PainReform Shares Surge in Registered Direct Offering


By Chris Wack


PainReform, a clinical-stage therapeutics reformulation company, saw its shares surge 19% to $9.65 on Monday following the announcement of a definitive agreement for the purchase and sale of 167,000 of its ordinary shares. The registered direct offering, priced at $9 a share, also included an unregistered warrant issuance for up to 167,000 shares. The offering is expected to close on or about Tuesday and is projected to generate approximately $1.5 million in proceeds. The funds will be allocated towards research and development, clinical trials, working capital, and general corporate purposes.

Share Surge and New High

On Friday, PainReform experienced a remarkable 41% increase in its stock price, reaching its peak of $26.41 per share for the past year on the preceding Tuesday.

Warrant Details

Simultaneously with the offering, the company will be conducting a private placement, issuing unregistered warrants. These warrants will allow investors to purchase up to 167,000 additional shares at an exercise price of $9 per share. The warrants become exercisable immediately upon issuance and will remain valid for a period of five years.

Expected Benefits

The anticipated $1.5 million in proceeds from this offering will be utilized to support various key initiatives, including research and development efforts, advancing clinical trials, fortifying working capital, and covering general corporate expenses.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Verizon Stock Faces Pressure Amidst Concerns Over Legacy Cables

Next Post

Stock Futures Point to Steady Start for Wall Street

Related Posts